ReviewFrontiers in immunology2026
The relationship between gut microbiota and cancer immune response and immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota critically regulates cancer immunity and immunotherapy outcomes. It does so through complex, bidirectional interactions with the host immune system. Key microbial metabolites drive this process. These include short-chain fatty acids (SCFAs), tryptophan derivatives, inosine, trimethylamine N-oxide (TMAO), and bile acids. These molecules direct immune cell differentiation and activity via pattern recognition receptor signaling and epigenetic regulation. Clinical studies have linked specific microbial compositions to responses to immune checkpoint inhibitors (ICIs) across multiple cancer types. These studies also highlight a dual role of the microbiota. It can both increase therapeutic efficacy and mitigate immune-related adverse events (irAEs). Several therapeutic strategies are under active investigation. These include fecal microbiota transplantation (FMT), probiotics, prebiotics, and dietary interventions. However, challenges remain regarding engraftment, standardization, and formulation consistency. Large-scale, well-designed studies are still needed. Such studies will help establish the gut microbiota as a reliable prognostic biomarker and a viable therapeutic adjunct in cancer immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.